Abstract
Background
Symptoms of depression and anxiety are common in patients with lung cancer and may produce an impact on both health-related quality of life (HRQL) and survival. The aim of the present study was to evaluate the association of depression and anxiety on HRQL, treatment adherence, and prognosis in patients with non-small cell lung cancer (NSCLC).
Methods
This is a prospective study of patients with stage IIIB or IV NSCLC. Depression and anxiety were measured using the hospital anxiety and depression scale, the International Neuropsychiatric Interview, and the HRQL with the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Instruments were applied before treatment and repeated at 3 and 6 months. Lack of treatment adherence was considered as patients who stopped going to their consultation appointments.
Results
A total of 82 patients were included. At the initial evaluation, depression and anxiety were found in 32.9 and 34.1 % of patients, respectively. Depression was associated with feminine gender (p = 0.034) and poor performance status (p = 0.048). Depression and anxiety showed an association with HRQL. Patients with depression showed median overall survival of 6.8 months, whereas that for nondepressed patients was 14 months (hazard ratio [HR], 1.9; 95 % confidence interval (95 % CI), 1.03–3.7; p = 0.042). The 58 % of patients with depression had poor treatment adherence versus 42 % of patients without depression (p = 0.004).
Conclusions
Depression and anxiety were present in one-third of patients with recently diagnosed NSCLC. Depression and anxiety were associated with decreased HRQL scales, and depression was independently associated with treatment adherence and with poor prognosis.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed 15 April 2012.
Medina-Morales F, Salazar-Flores M. Frecuencia y patrón cambiante del cáncer pulmonar en México. Salud Publica Mex. 2000;42:333–6.
Lazcano-Ponce EC, Tovar-Guzmán V, Meneses-González F, Rascon Pacheco RA, Hernandez Avila M. Trends of lung cancer mortality in Mexico. Arch Med Res. 1997;28:565–70.
D’Addario G, Felip E, ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:39–40.
Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.
NSCLC Meta-analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.
Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001;8:326–36.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525–31.
Pirl WF. Depresión, ansiedad y fatiga. In: Chabner BA, Lynch TJ, Longo DL, editors. Harrison’s Manual de Oncología. Mexico City: McGraw-Hill de Mexico; 2011. p. 190–6.
Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50:383–91.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.
Barton R, English A, Nabb S, Rigby AS, Johnson MJ. Randomised trial of high vs low intensity training in breathing techniques for breathless patients with malignant lung disease: a feasibility study. Lung Cancer. 2010;70:313–9.
Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A’Hern R. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ. 1999;318:901–4.
Skaug K, Eide GE, Gulsvik A. Prevalence and predictors of symptoms in the terminal stage of lung cancer: a community study. Chest. 2007;131:389–94.
Fayers PM, Machin D. Quality of life: assessment, analysis and interpretation. 2nd ed. New York: Wiley; 2007.
Carlsen K, Jensen AB, Jaconsen E, Krasnik M, Johansen C. Psychosocial aspects of lung cancer. Lung Cancer. 2005;47:293–4.
Pirl WF, Temel JS, Billings A, Dahlin C, Jackson V, Prigerson HG, et al. Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. Psychosomatics. 2008;49:218–24.
Nakaya N, Saito-Nakaya K, Akechi T, Kuriyama S, Inagaki M, Kikuchi N, et al. Negative psychological aspects and survival in lung cancer patients. Psychooncology. 2008;17:466–73.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
López-Alvarenga JC, Vázquez-Velázquez V, Arcila-Martínez D, Sierra-Ovando AE, González-Barranco J, Salín-Pascual RJ. Exactitud y utilidad diagnóstica del Hospital Anxiety and Depression Scale (HAD) en una muestra de sujetos obesos mexicanos [Accuracy and diagnostic utility of the Hospital Anxiety and Depression Scale (HAD) in a sample of obese Mexican patients]. Rev Invest Clin. 2002;54:403–9.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
Arrieta O, Núñez-Valencia C, Reynoso-Erazo L, Alvarado S, Flores-Estrada D, Angulo LP, et al. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer. 2012;77:205–11.
Bergman B, Aaronson NK, Ahmezdai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994; 30:635–42.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:356–76.
Arrarás JI, Pruja E, Marcos M, Tejedor M, Illarramendi JJ, Vera R, et al. El cuestionario de calidad de vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país. Oncologia. 2000;23:127–34.
Greene FL, Balch CM, Fleming ID, Fritz AG, Haller DG, Morrow M, et al. (eds). AJCC cancer staging handbook from the AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
Néron S, Correa JA, Dajczman E, Kasymjanova G, Kreisman H, Small D. Screening for depressive symptoms in patients with unresectable lung cancer. Support Care Cancer. 2007;15:1207–12.
Rolke HB, Bakke PS, Gallefoss F. HRQoL changes, mood disorders and satisfaction after treatment in an unselected population of patients with lung cancer. Clin Respir J. 2010;4:168–75.
Salvo N, Zeng L, Zhang L, Leung M, Khan L, Presutti R, et al. Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer. Clin Oncol (R Coll Radiol). 2012;24:139–48.
Sarna L. Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum. 1998;25:1041–8.
Whitney KA, Steiner AR, Lysaker PH, Estes DD, Hanna NH. Dimensional versus categorical use of the PHQ-9 Depression Scale among persons with non-small-cell lung cancer: a pilot study including quality-of-life comparisons. J Support Oncol. 2010;8:219–26.
Akechi T, Okamura H, Okuyama T, Furukawa TA, Nishiwaki Y, Uchitomi Y. Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. Psychooncology. 2009;18:23–9.
Chen ML, Chen MC, Yu CT. Depressive symptoms during the first chemotherapy cycle predict mortality in patients with advanced non-small cell lung cancer. Support Care Cancer. 2011;19:1705–11.
Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, et al. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. J Clin Oncol. 2012;20:1310–5.
Mazzoccoli G, Carughi S, De Cata A, La Viola M, Giuliani A, Tarquini R, et al. Neuroendocrine alterations in lung cancer patients. Neuro Endocrinol Lett. 2003;24:77–82.
Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R. Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer 2010;10:314.
Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.
Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5:617–25.
Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, Cella D, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 2005;3:37–50.
Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am. 1986;66:1121–35.
Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381–410.
Sanchez K, Turcott J, Juarez E, Villanueva G, Dorantes Y, Garralda M, et al. Nutritional parameters improve survival of patients with advanced non-small cell lung cancer during chemotherapy treatment. J Thorac Oncol. 2011;6:S1301–2.
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–7.
Satin JR, Linden WL, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients. Cancer. 2009;115:5349–61.
Acknowledgment
This project was supported partially by Instituto Nacional de Cancerología (INCan) and CONACYT (115574).
Conflict of interest
The authors have nothing to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arrieta, Ó., Angulo, L.P., Núñez-Valencia, C. et al. Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer. Ann Surg Oncol 20, 1941–1948 (2013). https://doi.org/10.1245/s10434-012-2793-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2793-5